BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 D’onofrio A, Silva F, Gano L, Raposinho P, Fernandes C, Sikora A, Wyczółkowska M, Mikołajczak R, Garnuszek P, Paulo A. Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers. Pharmaceutics 2022;14:2569. [DOI: 10.3390/pharmaceutics14122569] [Reference Citation Analysis]
2 Hernandez Vargas S, AghaAmiri S, Ghosh SC, Luciano MP, Borbon LC, Ear PH, Howe JR, Bailey-Lundberg JM, Simonek GD, Halperin DM, Tran Cao HS, Ikoma N, Schnermann MJ, Azhdarinia A. High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Mol Pharm 2022. [PMID: 36174110 DOI: 10.1021/acs.molpharmaceut.2c00583] [Reference Citation Analysis]
3 Ding J, Xu M, Chen J, Zhang P, Huo L, Kong Z, Liu Z. 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis. Mol Pharm 2022. [PMID: 35976352 DOI: 10.1021/acs.molpharmaceut.2c00579] [Reference Citation Analysis]
4 Kwon D, Zhang Z, Zeisler J, Kuo H, Lin K, Benard F. Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications. Pharmaceutics 2022;14:1502. [DOI: 10.3390/pharmaceutics14071502] [Reference Citation Analysis]
5 Refardt J, Klomp MJ, van Koetsveld PM, Dogan F, Konijnenberg M, Brabander T, Feelders RA, de Herder WW, Hofland LJ, Hofland J. Effect of epigenetic treatment on SST2 expression in neuroendocrine tumour patients. Clin Transl Med 2022;12:e957. [PMID: 35866246 DOI: 10.1002/ctm2.957] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Galbiati A, Zana A, Bocci M, Millul J, Elsayed A, Mock J, Neri D, Cazzamalli S. A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake.. [DOI: 10.1101/2022.02.21.481260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sakulpisuti C, Chamroonrat W, Tepmongkol S. Cutaneous Management after Extravasation of High-Concentrated Amino Acid Solution Administered for Renal Protection in PRRT. Tomography 2022;8:356-63. [DOI: 10.3390/tomography8010029] [Reference Citation Analysis]
8 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zaid NRR, Kletting P, Winter G, Prasad V, Beer AJ, Glatting G. A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice. Pharmaceutics 2021;13:2132. [PMID: 34959413 DOI: 10.3390/pharmaceutics13122132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]